FDA Determines Regulatory Review Period for ZUBRIN Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ZUBRIN, a patent extension application submitted to the Department of Commerce, and is publishing this official notice as required by law.